

Richard A. Summa, M.D.

Clinical Research Professionals
17998 Chesterfield Airport Rd., Suite 100
Chesterfield, MO 63005



Clinical
Research
Professionals

☎ 636.220.1200 Tel | 📠 314.667.3331 eFax

Education

1974-1978	B.A. Biochemistry	University of Missouri-Columbia
1978-1982	Doctor of Medicine	St. Louis University School of Medicine

Training

07/1982-06/1983	Internship	St. Mary's Health Center
07/1983-12/1983	Naval Flight Surgeon Training	Naval Air Station Pensacola, FL
07/1986-06/1988	Internal Medicine Residency	Naval Hospital San Diego
07/1988-06/1990	Fellowship Pulmonary & Critical Care Medicine	Naval Hospital San Diego

Professional Experience

07/2015 to Present	Investigator, Clinical Research Professionals 17998 Chesterfield Airport Rd., Suite 100, Chesterfield, MO 63005
09/1992 - Present	SSM Specialty Care (DePaul Health Center) 12255 DePaul Drive, Bridgeton, MO 63044
2005 - 2015	Director of Pulmonary Medicine, DePaul Health Center 12303 DePaul Drive, Bridgeton, MO 63044
1992 – 2013	Naval Reserves
03/2003 – 06/2003	Served as staff physician at Naval Medical Center, Portsmouth, VA
07/1990 - 08/1992	Staff Officer US Naval Hospital San Diego
01/1983 - 06/1986	Flight Surgeon, US Marine Corps/US Navy

Certification and Licensure

State of Missouri #R8D48
Board Certified in Internal Medical
Board Certified in Pulmonary Medicine
Board Certified in Critical Care Medicine - eligible

Awards

Naval Medals and Ribbons: Navy and Marine Corps Commendation Medal, Armed Forces Reserve Medal, National Defense Service Medal, Southwest Asia Service Ribbon, Kuwait Liberation Medal (Kuwait), Kuwait Liberation Medal (Sandia Arabia), Sharpshooter pistol, Armed Forces Expeditionary Medal, Fleet Marine Force Ribbon, Combat Action Ribbon

CLINICAL RESEARCH EXPERIENCE

1. A Phase III, 52 Week, Randomized, Double-blind, 3-arm Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination FF/UMEC/VI with the Fixed Dose Dual Combinations of FF/VI and UMEC/VI, All Administered Once-Daily in the Morning via a Dry Powder Inhaler in Subjects with **Chronic Obstructive Pulmonary Disease**, NCT02164513

2. A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for **Moderate to Severe Ulcerative Colitis**, NCT02435992
3. A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for **Moderate to Severe Ulcerative Colitis**, NCT02531126
4. A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients with **Type 2 Diabetes Mellitus** (AWARD-11: Assessment of Weekly Administration of LY2189265 in Diabetes-11), NCT03495102
5. Effect of LY3154207 on Cognition in **Mild-to-Moderate Parkinson's Disease Dementia** (PDD) (The PRESENCE Study), NCT03305809
6. A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients with **Gastroesophageal Reflux Disease** while receiving Proton Pump Inhibitors, NCT03561883
7. Phase 3, A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated with **Dementia-related Psychosis**, HARMONY Study, NCT03325556
8. Phase 3, Efficacy and Safety of LY3298176 Once Weekly versus Insulin Glargine in Patients with **Type 2 Diabetes and Increased Cardiovascular Risk**, SURPASS-4 Study, NCT03730662
9. A Phase 3, Randomized Observer-Blinded Study to Evaluate the Immunogenicity, Safety, and Tolerability of 2 Doses Compared to 3 Doses of **Clostridium Difficile Vaccine** in Adults 50 Years of Age or Older, B5091019, NCT03090191
10. A Randomized, Phase 3, Open-label Trial Comparing the Effect of LY3298176 versus Titrated Insulin Degludec on Glycemic Control in Patients with **Type 2 Diabetes**, SURPASS-3, NCT03882970
11. A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in **Migraine Prevention**, BHV3000-305, NCT03732638
12. A Randomized, Phase 3, Double-blind, Placebo-Controlled Trial Comparing the Efficacy of Three Tirzepatide Doses versus Placebo in Patients with **Type 2 Diabetes**, Inadequately Controlled with Diet and Exercise, SURPASS-I, NCT03954834